Construction of a Co-Expression Network for lncRNAs and mRNAs Related to Urothelial Carcinoma of the Bladder Progression.

Yeqing Mao,Zitong Yang,Chao Wen

doi:10.3389/fonc.2022.835074

Yeqing Mao, Zitong Yang + Show 1 more

Open Access

https://doi.org/10.3389/fonc.2022.835074

Copy DOI

Abstract

Carcinoma of urinary bladder is the most familiar cancer of the urinary tract, with the highest incidence in men. However, its prognosis and treatment have not improved significantly in the last 30 years. The main reason for this may be related to the alteration and regulation of genes. These alterations in genes that play a crucial role in cell cycle regulation may result in high-grade tumors and may alter drug sensitivity. Notably, the role of lncRNA in bladder cancer, especially the lncRNA-mRNA regulatory network, has not been fully elucidated. In this manuscript, we compared RNA sequencing (RNA-seq) data from 19 normal bladder tissues and 411 primary bladder tumor tissues using The Cancer Genome Atlas (TCGA) data bank, subjected differentially expressed mRNAs and lncRNAs to weighted gene co-expression network analysis, and screened out modules highly correlated with tumor progression. Subsequently, a lncRNA-mRNA co-expression network was built, and two key mRNAs were identified via COX regression analysis. Kaplan-Meier curve analysis revealed that the overall survival of sick people in the high-risk section was significantly shorter than those in the low-risk section. Therefore, this lncRNA-mRNA-based co-expression pattern may be used clinically to predict the prognosis of carcinoma of urinary bladder people. Our study not only provides a genetic target for carcinoma of urinary bladder therapy but also provides new ideas for people in the medical profession to discover the treatment of various tumors.

Highlights

Carcinoma of urinary bladder is one of the most familiar malignancies worldwide [1], dominated by urothelial carcinoma of the bladder (BLCA), which accounts for approximately 90% of bladder cancers [2]
This study identified mRNAs and lncRNAs differentially expressed during bladder cancer progression based on 411 BLCA patient samples from The Cancer Genome Atlas (TCGA) database, subjected them to weighted gene coexpression network analysis (WGCNA), and confirmed mRNAs and lncRNAs associated with bladder cancer progression
In order to probe the co-expression patterns of mRNAs and lncRNAs in BLCA, we screened 3,394 differentially expressed lncRNAs and 2,379 differentially expressed mRNAs obtained from the TCGA database for WGCNA analysis

Summary

Introduction

Carcinoma of urinary bladder is one of the most familiar malignancies worldwide [1], dominated by urothelial carcinoma of the bladder (BLCA), which accounts for approximately 90% of bladder cancers [2]. The traditional cure for carcinoma of urinary bladder mainly include surgical excision and chemotherapy. Bladder Urothelial Carcinoma Progression limited for advanced bladder cancer [6, 7]. This high recurrence rate may be partly explained by the poorly understood pathogenesis of BCa [8]. Exploring the pathogenesis of BCa and identifying accurate and effective biomarkers based on its clinical spectrum is vital for early diagnosis without obvious clinical symptoms, assessment of prognosis, and the development of effective treatment strategies

Methods

Results

Conclusion